<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006939.pub2" GROUP_ID="MOVEMENT" ID="546305021509505222" MERGED_FROM="" MODIFIED="2017-03-09 17:35:16 +0000" MODIFIED_BY="Ema Roque" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2017-03-09 17:25:43 +0000" NOTES_MODIFIED_BY="Ema Roque" REVIEW_NO="002" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2017-03-09 17:23:22 +0000" MODIFIED_BY="Ema Roque">
<TITLE>Benzodiazepines for restless legs syndrome</TITLE>
<CONTACT>
<PERSON ID="38D0FA0C82E26AA201BA4B547DC85853" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Gilmar</FIRST_NAME>
<MIDDLE_INITIALS>F</MIDDLE_INITIALS>
<LAST_NAME>Prado</LAST_NAME>
<SUFFIX/>
<POSITION>Professor</POSITION>
<EMAIL_1>gilmarunifesp@yahoo.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>Escola Paulista de Medicina, Universidade Federal de São Paulo</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP/>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 11 5081 6629</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2017-03-09 17:04:49 +0000" MODIFIED_BY="Ema Roque">
<PERSON ID="z1310211137131893921692831170592" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Karla</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Carlos</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>Ka.carlos1@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>Escola Paulista de Medicina, Universidade Federal de São Paulo</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="38D0FA0C82E26AA201BA4B547DC85853" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Gilmar</FIRST_NAME>
<MIDDLE_INITIALS>F</MIDDLE_INITIALS>
<LAST_NAME>Prado</LAST_NAME>
<SUFFIX/>
<POSITION>Professor</POSITION>
<EMAIL_1>gilmarunifesp@yahoo.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>Escola Paulista de Medicina, Universidade Federal de São Paulo</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP/>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 11 5081 6629</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="31885356889310740238110210094318" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Camila</FIRST_NAME>
<MIDDLE_INITIALS>DM</MIDDLE_INITIALS>
<LAST_NAME>Teixeira</LAST_NAME>
<SUFFIX/>
<POSITION>Psychologist</POSITION>
<EMAIL_1>camilademasi@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>Escola Paulista de Medicina, Universidade Federal de São Paulo</ORGANISATION>
<ADDRESS_1>Rua Dr. Natalino Righeto - 160</ADDRESS_1>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP>02303-130</ZIP>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 11 2203 7422</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="73EBB10682E26AA201E0E19D9634A52F" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Cristiane</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Conti</LAST_NAME>
<SUFFIX/>
<POSITION>Clinical Neurologist, PhD</POSITION>
<EMAIL_1>contic@terra.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Morphology</DEPARTMENT>
<ORGANISATION>Universidade Federal do Maranhão</ORGANISATION>
<ADDRESS_1>Av. dos Portugueses, 1966</ADDRESS_1>
<ADDRESS_2>Bacanga</ADDRESS_2>
<CITY>São Luis</CITY>
<ZIP>65080-805</ZIP>
<REGION>Maranhão</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 98 32728521</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="AFBB514F82E26AA20100271A20CF4B41" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Marcio</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>de Oliveira</LAST_NAME>
<SUFFIX/>
<POSITION>Physician</POSITION>
<EMAIL_1>docmmo@uol.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Morphology</DEPARTMENT>
<ORGANISATION>Universidade Federal do Maranhão</ORGANISATION>
<ADDRESS_1>Av dos Portugueses 1966</ADDRESS_1>
<ADDRESS_2>Bacanga</ADDRESS_2>
<CITY>São Luis</CITY>
<ZIP>65080-805</ZIP>
<REGION>Maranhão</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7B97BA2482E26AA2014A55948F8A57B9" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Lucila</FIRST_NAME>
<MIDDLE_INITIALS>BF</MIDDLE_INITIALS>
<LAST_NAME>Prado</LAST_NAME>
<SUFFIX/>
<POSITION>Clinical Coordinator of Neuro-Sono Sleep Medicine</POSITION>
<EMAIL_1>lucilaunifesp@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>Escola Paulista de Medicina, Universidade Federal de São Paulo</ORGANISATION>
<ADDRESS_1>Rua Claudio Rossi,394</ADDRESS_1>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP>01547-000</ZIP>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 11 5081 6629</PHONE_1>
<PHONE_2>+55 11 55728205</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="71568C7F82E26AA200CE0284C573E0D4" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Luciane</FIRST_NAME>
<MIDDLE_INITIALS>BC</MIDDLE_INITIALS>
<LAST_NAME>Carvalho</LAST_NAME>
<SUFFIX>PhD</SUFFIX>
<POSITION/>
<EMAIL_1>lucianebizari@yahoo.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>Escola Paulista de Medicina, Universidade Federal de São Paulo</ORGANISATION>
<ADDRESS_1>Rua Claudio Rossi, 394</ADDRESS_1>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP>CEP 01547-000</ZIP>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 11 50816629</PHONE_1>
<PHONE_2>+55 11 50816629</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2016-03-22 23:31:42 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="22" MONTH="3" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="22" MONTH="3" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="22" MONTH="3" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2008"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2017"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2017"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="6" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY/>
<SOURCES_OF_SUPPORT MODIFIED="2017-03-09 17:23:22 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2017-03-09 17:23:22 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2017-03-09 17:23:00 +0000" MODIFIED_BY="[Empty name]">
<NAME>CAPES - Programa Demanda Social</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2017-03-09 17:23:22 +0000" MODIFIED_BY="[Empty name]">
<NAME>CNPq - Process # 300646/2013-5</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-03-09 17:25:43 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2017-02-14 10:40:48 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2016-08-31 21:38:02 +0100" MODIFIED_BY="[Empty name]">Benzodiazepines for restless legs syndrome</TITLE>
<SUMMARY_BODY MODIFIED="2017-02-14 10:40:48 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Background</B>
</P>
<P>Restless legs syndrome (RLS) is a common and distressing disease affecting 5% to 15% of the population. Many physicians are still unaware of the disease and do not recognize its symptoms. This disease can affect sleep significantly, impairing quality of life. There is a need for safe and effective treatment for RLS. Current treatments include dopamine agonists, anticonvulsants, and opioids.</P>
<P>
<B>Question</B>
</P>
<P>Are benzodiazepines effective and safe for people with RLS?</P>
<P>
<B>Methods</B>
</P>
<P>We searched the literature for studies in any language, published or not, that considered benzodiazepines for the treatment of RLS.</P>
<P>
<B>Results</B>
</P>
<P>No studies were included in the review.</P>
<P>
<B>Discussion</B>
</P>
<P>Benzodiazepines have been used for a long time in people with RLS, because these drugs help sleep initiation and maintenance. As there was no properly conducted systematic review on the effectiveness of benzodiazepines, we performed one on this topic.</P>
<P>
<B>Conclusion</B>
</P>
<P>This systematic review shows that there is no good data to support or refute the use of benzodiazepines to treat symptoms of RLS.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2017-03-09 17:25:43 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2017-02-14 10:25:47 +0000" MODIFIED_BY="[Empty name]">
<P>Restless legs syndrome (RLS) is a common disease affecting about 5% to 15% of the population. Symptoms of RLS can be severe in a minority of and can have a major impact on sleep, mostly sleep initiation, and quality of life. Benzodiazepines are drugs that can induce and maintain sleep and, hence, intuitively are thought to be beneficial to people with RLS. Altough benzodiazepines, particularly clonazepam, are used to treat RLS symptoms, a systematic review done by the American Academy of Sleep Medicine stated that benzodiazepines should not be used as a first-line treatment, although could be used as a coadjuvant therapy.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2017-03-09 17:25:43 +0000" MODIFIED_BY="[Empty name]">
<P>To evaluate the efficacy and safety of benzodiazepine compared to placebo or other treatment for idiopathic RLS, including unconfounded trials comparing benzodiazepines versus open control.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2017-02-14 10:27:53 +0000" MODIFIED_BY="[Empty name]">
<P>In March 2016 we searched CENTRAL, MEDLINE, Embase and LILACS We checked the references of each study and contacted study authors to identify any additional studies. We considered studies published in any language.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2017-02-14 10:28:06 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trials of benzodiazepine treatment in idiopathic RLS.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2017-03-09 11:16:20 +0000" MODIFIED_BY="[Empty name]">
<P>We did not perform data collection and analysis, since we did not include any studies, </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2017-02-14 10:39:27 +0000" MODIFIED_BY="[Empty name]">
<P>We did not identify any studies that met the inclusion criteria of the review. Two cross-over studies are awaiting classification because the cross-over trials did not give data at the end of the first cross-over period.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2017-02-09 14:19:23 +0000" MODIFIED_BY="[Empty name]">
<P>The effectiveness of benzodiazepines for RLS treatment is currently unknown.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-03-09 17:25:33 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2017-02-14 10:46:32 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2017-02-14 10:42:44 +0000" MODIFIED_BY="[Empty name]">
<P>Restless Legs Syndrome (RLS) is a sensory motor disorder characterized by a distressing urge to move the legs and, sometimes, other parts of the body as well, usually accompanied by a marked sense of discomfort or pain in the legs or other affected body parts (<LINK REF="REF-Allen-2003" TYPE="REFERENCE">Allen 2003</LINK>).</P>
<P>The prevalence of RLS is estimated at 5% to 15% in adults, and many physicians do not recognize its symptoms (<LINK REF="REF-Carlos-2015" TYPE="REFERENCE">Carlos 2015</LINK>). It is more common in women, and can affect children as well (<LINK REF="REF-Picchietti-2005" TYPE="REFERENCE">Picchietti 2005</LINK>; <LINK REF="REF-Picchietti-2007" TYPE="REFERENCE">Picchietti 2007</LINK>; <LINK REF="REF-Yeh-2012" TYPE="REFERENCE">Yeh 2012</LINK>). When frequency or severity of symptoms, or both, are added to the diagnostic criteria, the prevalence of RLS ranges from 2.2% to 7.9%. If the diagnosis is based in a clinical interview, taking into account all possible differential diagnosis, the prevalence declines to between 1.9% and 4.6% (<LINK REF="REF-Ohayon-2012" TYPE="REFERENCE">Ohayon 2012</LINK>; <LINK REF="REF-Picchietti-2005" TYPE="REFERENCE">Picchietti 2005</LINK>).</P>
<P>Other features commonly found in adults with RLS include sleep disturbance, daytime fatigue, and decreased quality of life ratings (<LINK REF="REF-Picchietti-2005" TYPE="REFERENCE">Picchietti 2005</LINK>), mostly in people who also have iron deficiency anaemia (<LINK REF="REF-Allen-2013" TYPE="REFERENCE">Allen 2013</LINK>; <LINK REF="REF-Picchietti-2005" TYPE="REFERENCE">Picchietti 2005</LINK>).</P>
<P>The physical examination is typically normal. RLS may be either idiopathic (primary RLS, which often has a familial component) or secondary (occurring in conjunction with other medical conditions, particularly iron deficiency anaemia, pregnancy, or end-stage renal disease). Secondary RLS tends to remit without evidence of reoccurrence when the secondary condition is resolved - for example, after renal transplantation in people with end-stage renal disease, and postpartum in women with RLS occurring in pregnancy (<LINK REF="REF-Lee-2001" TYPE="REFERENCE">Lee 2001</LINK>; <LINK REF="REF-H_x00fc_bner-2013" TYPE="REFERENCE">Hübner 2013</LINK>; <LINK REF="REF-Winkelmann-2002" TYPE="REFERENCE">Winkelmann 2002</LINK>).</P>
<P>Periodic leg movements in sleep (PLMS) are characterized by brief (0.5- to 5.0-second) lower-extremity movements during sleep, which typically occur at 20- to 90-second intervals, most commonly during the first three hours of sleep (<LINK REF="REF-AASM-2005" TYPE="REFERENCE">AASM 2005</LINK>). The affected individual is usually not aware of the movements or of the associated transient partial arousals (<LINK REF="REF-Picchietti-2005" TYPE="REFERENCE">Picchietti 2005</LINK>; <LINK REF="REF-Trenkwalder-2005" TYPE="REFERENCE">Trenkwalder 2005</LINK>). Recently some data have suggested that PLMS are associated with adverse cardiovascular outcome and cardiac hypertrophy (<LINK REF="REF-Mirza-2013" TYPE="REFERENCE">Mirza 2013</LINK>). Eighty to ninety per cent of individuals with RLS have PLMS, but PLMS is not specific to RLS (<LINK REF="REF-Rye-2012" TYPE="REFERENCE">Rye 2012</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2017-02-14 10:46:14 +0000" MODIFIED_BY="[Empty name]">
<P>The treatment of RLS includes pharmacological and non-pharmacological therapies. The most common pharmacological agents used in clinical practice for the treatment of RLS are levodopa, dopamine agonists, opioids, benzodiazepines, and anticonvulsants (<LINK REF="REF-Garcia_x002d_Borreguero-2013" TYPE="REFERENCE">Garcia-Borreguero 2013</LINK>; <LINK REF="REF-Trenkwalder-2005" TYPE="REFERENCE">Trenkwalder 2005</LINK>). The treatment of isolated PLMS is still controversial (<LINK REF="REF-Hornyak-2006" TYPE="REFERENCE">Hornyak 2006</LINK>).</P>
<P>Benzodiazepines have been used for treatment or prophylaxis of seizure, psychiatric disorders, and pain syndromes, although no evidence supports the use of clonazepam, a frequently used benzodiazepine drug to treat RLS, in chronic neuropathic pain (<LINK REF="REF-Corrigan-2012" TYPE="REFERENCE">Corrigan 2012</LINK>).</P>
<P>The central nervous system activity of benzodiazepines occurs mainly by potentiation of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter. Other mechanisms, such as an increase in central synthesis of serotonin, may also be responsible for this activity but the mechanism by which benzodiazepines improve RLS is not clear (<LINK REF="REF-Joy-1997" TYPE="REFERENCE">Joy 1997</LINK>).</P>
<P>Benzodiazepines are given in RLS to improve the quality of sleep and reduce PLMS (<LINK REF="REF-Saletu-2001" TYPE="REFERENCE">Saletu 2001</LINK>) although the American Academy of Sleep Medicine Practice Guideline does not recommend benzodiazepines as first-line treatment (<LINK REF="REF-Aurora-2012" TYPE="REFERENCE">Aurora 2012</LINK>). They may also ameliorate the waking symptoms of RLS, but this finding is less well established, and the use of these drugs in the daytime is limited by risks of sedation. The inappropriate use of benzodiazepines also can lead to psychological dependence and physiological tolerance. Known adverse effects are increased risk of falling, sedation, drowsiness, ataxia, muscular inco-ordination, hypotonia, and dysarthria. Behavioral disturbances such as aggressiveness, irritability, agitation, and hyperkinesis have occurred principally in children (<LINK REF="REF-Glass-2005" TYPE="REFERENCE">Glass 2005</LINK>). Benzodiazepines can also worsen obstructive sleep apnoea syndrome (<LINK REF="REF-Guilleminault-1990" TYPE="REFERENCE">Guilleminault 1990</LINK>; <LINK REF="REF-Horguchi-1992" TYPE="REFERENCE">Horguchi 1992</LINK>).</P>
<P>The essentially normal presynaptic dopaminergic binding studies using F-dopa PET or beta-CIT-SPECT (imaging diagnostic tools) in people with RLS lend support to the hypothesis that dopaminergic neurons and spinal pathways could be more involved in the pathophysiological mechanisms of the syndrome than the nigrostriatal system (<LINK REF="REF-Wetter-2004" TYPE="REFERENCE">Wetter 2004</LINK>).</P>
<P>Although dopamine can be increased in the synaptic cleft of people with RLS, the strongest evidence for a dopaminergic role in the pathophysiology of RLS comes from the pharmacological response to medications that increase dopamine function (<LINK REF="REF-Allen-2004" TYPE="REFERENCE">Allen 2004</LINK>; <LINK REF="REF-Earley-2013" TYPE="REFERENCE">Earley 2013</LINK>). Functional imaging studies have shown reduced fluorodopa uptake or reduced D2 receptor binding in the corpus striatum (<LINK REF="REF-Wetter-2004" TYPE="REFERENCE">Wetter 2004</LINK>).</P>
<P>Iron is a cofactor in dopamine production and there is a brain iron deficiency in people with RLS. Studies with iron-deprived rats indicate that low CSF ferritin and high transferrin can be expected to occur with reduced brain iron (<LINK REF="REF-Allen-2004" TYPE="REFERENCE">Allen 2004</LINK>; <LINK REF="REF-Rizzo-2013" TYPE="REFERENCE">Rizzo 2013</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2017-02-14 10:46:27 +0000" MODIFIED_BY="[Empty name]">
<P>Benzodiazepines may be useful in the treatment of RLS because they act as hypnotic drugs, reducing sleep latency, prolonging total sleep time, reducing waking after sleep onset, and diminishing the arousal threshold (<LINK REF="REF-Bostwick-2012" TYPE="REFERENCE">Bostwick 2012</LINK>; <LINK REF="REF-Howard-2014" TYPE="REFERENCE">Howard 2014</LINK>
 ). Furthermore, these drugs reduce anxiety which is frequently associated with RLS (<LINK REF="REF-Brand-2013" TYPE="REFERENCE">Brand 2013</LINK>). Although some features of these drugs may benefit people with RLS, others might act in the opposite way: for instance this class of drugs may act as opioid antagonists attenuating opioid anti nociception (<LINK REF="REF-Daghero-1987" TYPE="REFERENCE">Daghero 1987</LINK>; <LINK REF="REF-Gear-1997" TYPE="REFERENCE">Gear 1997</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2017-02-14 10:46:32 +0000" MODIFIED_BY="[Empty name]">
<P>RLS is a frequent sleep disorder affecting 5% to 15% of the general population, impacting negatively on their quality of life. Dopaminergic agonists, L-Dopa, opioids, anticonvulsants are frequently-used medications to alleviate the symptoms of RLS, but some people do not respond to these drugs or have side effects that prevent their use. Whilst the AASM (<LINK REF="REF-Aurora-2012" TYPE="REFERENCE">Aurora 2012</LINK>) Clinical Practice Guideline advised against the use of benzodiazepines as first-line agents for RLS, it was not constructed with sufficient scientific and methodological rigour to permit definitive conclusions. At any rate, the Guideline does state that clonazepam can be used as an adjunctive medication, and benzodiazepines, mostly clonazepam, have been used to reduce the symptoms of RLS for many years.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2017-03-09 17:25:33 +0000" MODIFIED_BY="[Empty name]">
<P>To evaluate the efficacy and safety of benzodiazepine compared to placebo or other treatment for idiopathic RLS, including unconfounded trials comparing benzodiazepines versus open control.</P>
</OBJECTIVES>
<METHODS MODIFIED="2017-03-09 17:25:26 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2017-03-09 17:25:26 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2017-02-14 10:46:41 +0000" MODIFIED_BY="[Empty name]">
<P>All randomized controlled trials (RCTs) and quasi-RCTs (quasi-RCTs are defined as trials using inadequate allocation assignment such as date of birth, day of the week or month of the year, person's medical record number, or just allocating every alternate person). We considered either studies with a parallel-group or a cross-over design.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2017-03-09 17:25:26 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<P>We considered children and adults who met any clinical criteria for idiopathic RLS (<LINK REF="REF-ASDA-1990" TYPE="REFERENCE">ASDA 1990</LINK>; <LINK REF="REF-DCSAD-1979" TYPE="REFERENCE">DCSAD 1979</LINK>; <LINK REF="REF-ICSD-2014" TYPE="REFERENCE">ICSD 2014</LINK>; <LINK REF="REF-Walters-1995" TYPE="REFERENCE">Walters 1995</LINK>). The clinical diagnostic criteria lists four essential components (<LINK REF="REF-Allen-2003" TYPE="REFERENCE">Allen 2003</LINK>).</P>
<OL>
<LI>An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs (sometimes the urge to move is present without the uncomfortable sensations, and sometimes the arms or other body parts are involved in addition to the legs).</LI>
<LI>The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity, such as lying or sitting.</LI>
<LI>The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.</LI>
<LI>The urge to move or unpleasant sensations are worse in the evening or night than during the day, or only occur in the evening or night (when symptoms are very severe, the worsening at night may not be noticeable but must have been previously present).
</LI>
</OL>
<P>We excluded studies exclusively examining people with PLMD (periodic movement limb disorder), without symptoms of RLS. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<P>We excluded studies that included people with secondary forms of RLS, such as metabolic, neuropathic, or renal disease.</P>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-09-21 13:11:57 +0100" MODIFIED_BY="[Empty name]">
<P>We included unconfounded trials comparing benzodiazepine drugs to placebo or no treatment (open control) as well as trials comparing benzodiazepines to other treatments, pharmacological or not.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2017-02-14 11:01:36 +0000" MODIFIED_BY="[Empty name]">
<P>We included short-term and long-term studies.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2017-02-14 11:01:13 +0000" MODIFIED_BY="[Empty name]">
<P>Improvement of RLS symptoms, as assessed by a validated scale (<LINK REF="REF-Allen-2001" TYPE="REFERENCE">Allen 2001</LINK>; <LINK REF="REF-IRLSSG-2003" TYPE="REFERENCE">IRLSSG 2003</LINK>).</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2017-02-14 11:01:36 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Subjective sleep quality (any description about sleep quality, i.e. well-being, improvement of fatigue)</LI>
<LI>Sleep quality, as measured by overnight polysomnography (sleep efficiency, total sleep time, arousal index, PLMS index)</LI>
<LI>Quality of life, as measured by a validated scale, such as SF-36</LI>
<LI>Adverse events described in terms of:</LI>
<OL>
<LI>number of withdrawals due to adverse events;</LI>
<LI>number of participants with any adverse events associated with the interventions.</LI>
</OL>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2017-03-09 17:25:06 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2017-02-14 11:06:33 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) 2016, Issue 4, in the Cochrane Library (accessed March 2016; <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</LI>
<LI>MEDLINE (1966 to March 2016), using the optimally sensitive search strategy developed for the Cochrane Collaboration for the identification of randomized controlled trials in MEDLINE (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</LI>
<LI>Embase (1980 to March 2016), using a search strategy adapted from that developed for the Cochrane Collaboration for the identification of randomized controlled clinical trials (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</LI>
<LI> LILACS (1982 to March 2016), using a search strategy adapted from that developed for the Cochrane Collaboration for the identification of randomized controlled clinical trials (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</LI>
</OL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2017-03-09 17:25:06 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed references from original papers and abstracts, reviews, systematic reviews, meta-analyses, and ongoing and unpublished trials registers (World Health Organization (WHO) <A HREF="http://www.who.int/ictrp/en/">International Clinical Trials Registry Platform (ICTRP)</A>; <A HREF="https://www.clinicaltrials.gov/">ClinicalTrials.gov</A>) were assessed to identify any additional studies. We contacted some researchers in the field of RLS to ask if they knew of any relevant unpublished material.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2017-03-09 17:25:13 +0000" MODIFIED_BY="[Empty name]">
<P>We planned to use the GRADE approach to assess the quality of the evidence for each outcome across any included trials.</P>
<STUDY_SELECTION MODIFIED="2017-02-16 09:49:05 +0000" MODIFIED_BY="[Empty name]">
<P>We used the search strategies described above to obtain titles and abstracts of relevant studies, which were independently screened by LC and KC.</P>
<P>They initially retained review articles that might include relevant data or information on trials. The review authors independently assessed the retrieved abstracts, and if necessary, the full texts of these studies, to determine which studies met the inclusion criteria.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2017-03-09 17:25:13 +0000" MODIFIED_BY="[Empty name]">
<P>Since we did not include any study, there was no data extraction performed.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2017-02-14 11:38:54 +0000" MODIFIED_BY="[Empty name]">
<P>We planned to assess, independently, the risk of bias of any included studies without blinding to authorship or journal, resolving any disagreement by discussion. We would have incorporated the 'Risk of bias' assessments into the 'Risk of bias' tables, as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We planned to consider: adequate sequence generation, allocation concealment, blinding of participants, personnel, and outcome assessment, incomplete outcome data, selective outcome reporting, and other biases and to assign 'Low risk', 'High risk', or 'Unclear risk' judgements to each criterion. 'Unclear risk' would indicate that there was insufficient information to permit a clear judgement.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2017-02-14 11:40:20 +0000" MODIFIED_BY="[Empty name]">
<P>For dichotomous variables we planned to calculate the risk ratio (RR) with 95% confidence interval (CI), using the random-effects model. For continuous outcomes we planned to calculate mean differences (MD) or standardized mean differences (SMD) with 95% CI, using the random-effects model. We would have used SMD to measure the same outcomes on different scales. We planned to analyse both change and endpoint data.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2017-03-09 11:16:29 +0000" MODIFIED_BY="[Empty name]">
<P>In future updates, we planned to include cross-over trials if they report data in sufficient detail to enable us to incorporate this in to the review according to the recommendations of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>). We plan to evaluate two cross-over periods with a paired analysis, and assess the impact of a carry-over effect as part of the 'Risk of bias' assessment.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2017-02-14 11:41:33 +0000" MODIFIED_BY="[Empty name]">
<P>In suspected cases of missing data, we planned to contact the primary investigator of the study. In addition, we would perform a worst case scenario analysis, considering participants with missing data as treatment failures.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2017-02-14 11:42:43 +0000" MODIFIED_BY="[Empty name]">
<P>We planned to assess heterogeneity with the Chi<SUP>2</SUP> test, which we would have assumed to be present when the significance level (P value) was lower than 0.10, and with the I<SUP>2</SUP> test, assuming substantial heterogeneity when I<SUP>2</SUP> was greater than 50% (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). If significant heterogeneity were present, we would attempt to explain the differences based on clinical characteristics of any included studies.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2017-02-14 11:43:39 +0000" MODIFIED_BY="[Empty name]">
<P>To reduce reporting bias, we contacted as many authors involved in RLS research as possible, and asked about any unpublished trials they might be aware of. We also searched in the International Committee of Medical Journal Editors for trials that had been registered and not published. We had planned to use a funnel plot (trial effect versus trial size) to explore the possibility of publication bias, if we found sufficient studies (10 or more) for any of the primary analyses.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2017-02-14 11:45:41 +0000" MODIFIED_BY="[Empty name]">
<P>For clinically homogeneous studies, we intended to pool the data in a meta-analysis, using the fixed-effect model as a default, and the inverse variance method.</P>
<SUBSECTION>
<HEADING LEVEL="3">GRADE and 'Summary of findings' table</HEADING>
<P>We would have used the GRADE approach to assess the quality of the evidence for each outcome across any included trials, and to present the results in a 'Summary of findings' table. We planned to categorize the primary outcomes at the highest level, and downgrade them due to the following study limitations: limitations in design, inconsistency of results, indirectness of evidence, imprecision of results, and publication bias. We would have decreased the quality of the evidence by one point in case of serious problems with the risk of bias criteria, or two points if there were very serious problems.</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2017-02-14 11:46:47 +0000" MODIFIED_BY="[Empty name]">
<P>Had sufficient data been available, we would have carried out subgroup analyses according to subcategory to explore possible sources of heterogeneity as follows.</P>
<OL>
<LI>Age (children and adults)</LI>
<LI>Severity (mild, moderate and severe)</LI>
<LI>Gender</LI>
<LI>Length of treatment</LI>
<LI>Ethnic group</LI>
<LI>Type of medication</LI>
<OL>
<LI>clonazepam</LI>
<LI>temazepam</LI>
<LI>flurazepam</LI>
<LI>quazepam</LI>
<LI>estazolam</LI>
<LI>triazolam</LI>
<LI>alprazolam</LI>
<LI>diazepam</LI>
<LI>clobazam</LI>
<LI>lorazepam</LI>
<LI>oxazepam</LI>
<LI>zolpidem</LI>
<LI>zaleplon</LI>
<LI>zopiclone</LI>
<LI>eszopiclone</LI>
</OL>
</OL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2017-02-16 13:58:39 +0000" MODIFIED_BY="[Empty name]">
<P>We planned to perform sensitivity analysis through assessment of the methodological characteristics of the included studies, as well as of the clinical characteristics of their participants, using the following strategies.</P>
<OL>
<LI>Separating RCTs published as abstracts</LI>
<LI>Separating RCTs of high risk of bias as assessed by allocation concealment</LI>
<LI>Separating RCTs without an intention-to-treat analysis</LI>
<LI>Separating cross-over studies from the analysis</LI>
<LI>Age (children and adults)</LI>
<LI>Severity (mild, moderate, severe)</LI>
<LI>Gender</LI>
<LI>Length of treatment</LI>
<LI>Ethnic group</LI>
<LI>Medication</LI>
</OL>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-02-14 11:50:00 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2017-02-14 11:50:00 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2017-02-14 11:49:18 +0000" MODIFIED_BY="[Empty name]">
<P>Our search of electronic databases yielded a total of 1518 publications (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>): 246 records in CENTRAL, 280 in MEDLINE, 989 in Embase, and 3 in LILACS, with 118 duplicate records. After analysing titles and summaries, we selected three of these publications full-text analysis (<LINK REF="STD-Boghen-1986" TYPE="STUDY">Boghen 1986</LINK>; <LINK REF="STD-Manconi-2012" TYPE="STUDY">Manconi 2012</LINK>; <LINK REF="STD-Montagna-1984" TYPE="STUDY">Montagna 1984</LINK>). Two small cross-over studies are awaiting classification (<LINK REF="STD-Boghen-1986" TYPE="STUDY">Boghen 1986</LINK>; <LINK REF="STD-Montagna-1984" TYPE="STUDY">Montagna 1984</LINK>). Both of these studies had short washout periods for clonazepam and there was a lack of analysis based on the paired-results. Uncertainty over how far the results of these studies are affected by possible carry-over effects, together with the age of the studies, led us to list them as awaiting classification. (<LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-02-16 19:21:14 +0000" MODIFIED_BY="[Empty name]">
<P>No studies were included.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2017-02-14 11:50:00 +0000" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Manconi-2012" TYPE="STUDY">Manconi 2012</LINK> was a one-night-only, single-blind, placebo-controlled study where the intervention was mostly designed to evaluate neurophysiological variables in this particular group of people and not to treat RLS.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2017-02-09 17:05:20 +0000" MODIFIED_BY="[Empty name]">
<P>Not applicable</P>
<ALLOCATION MODIFIED="2017-02-09 17:05:19 +0000" MODIFIED_BY="[Empty name]">
<P>Not applicable</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-08-24 15:15:49 +0100" MODIFIED_BY="[Empty name]">
<P>Not applicable</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-08-24 15:15:49 +0100" MODIFIED_BY="[Empty name]">
<P>Not applicable</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-03-22 23:23:33 +0000" MODIFIED_BY="[Empty name]">
<P> Not applicable</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-08-24 15:15:49 +0100" MODIFIED_BY="[Empty name]">
<P>Not applicable</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-08-24 15:15:49 +0100" MODIFIED_BY="[Empty name]">
<P>Not applicable</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2017-02-14 11:51:13 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2017-02-14 11:50:27 +0000" MODIFIED_BY="[Empty name]">
<P>This review does not provide evidence to assess the effects of benzodiazepines in the treatment of RLS. Two studies from three that were selected to be read in full are awaiting classification (<LINK REF="STD-Boghen-1986" TYPE="STUDY">Boghen 1986</LINK>; <LINK REF="STD-Montagna-1984" TYPE="STUDY">Montagna 1984</LINK>). Lack of detailed information prevented us from using data.</P>
<P>Given our lack of knowledge about the role of clonazepam or other benzodiazepines in the treatment of RLS, only well-designed clinical trials will answer this question. This is of relevance, since clonazepam is suggested to be of benefit in the control of augmentation related to the treatment of RLS, an emergent clinical problem associated with the use of dopaminergic agonists for RLS (<LINK REF="REF-Kurlan-2013" TYPE="REFERENCE">Kurlan 2013</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2017-02-14 11:50:33 +0000" MODIFIED_BY="[Empty name]">
<P>It was not possible to include any studies in this review, so our research question was not answered, and the value of benzodiazepines in the treatment of RLS is still unknown.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-09-01 20:12:37 +0100" MODIFIED_BY="[Empty name]">
<P>There is no evidence about the effect or absence of effect of benzodiazepines for RLS.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-08-24 15:15:49 +0100" MODIFIED_BY="[Empty name]">
<P>It is always possible that some unpublished studies (usually those showing negative results) exist but were not identified by our searches. It is also possible that the excluded trials could bring some relevant information if the individual data were assessed.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2017-02-14 11:51:13 +0000" MODIFIED_BY="[Empty name]">
<P>Although this review did not find any scientific evidence regarding the value of benzodiazepines for RLS, two case series suggest that benzodiazepines can be of some help for people with RLS (<LINK REF="REF-Saletu-2001" TYPE="REFERENCE">Saletu 2001</LINK>; <LINK REF="REF-Schenck-1996" TYPE="REFERENCE">Schenck 1996</LINK>), as they may improve the effectiveness and quality of sleep, and suggest that clonazepam in particular may be effective in inducing sleep in these people; however, neither of these case series provide specific data on RLS symptoms, and their conclusions are based on indirect improvement of RLS as measured by improvement in sleep quality. A 1999 AASM review (<LINK REF="REF-Hening-1999" TYPE="REFERENCE">Hening 1999</LINK>) suggested benzodiazepines as an option for the treatment of RLS. The 2012 update of this review, however (<LINK REF="REF-Aurora-2012" TYPE="REFERENCE">Aurora 2012</LINK>), did not recommend use of this pharmacological class, although both versions were based on the same primary studies (<LINK REF="STD-Boghen-1986" TYPE="STUDY">Boghen 1986</LINK>; <LINK REF="STD-Montagna-1984" TYPE="STUDY">Montagna 1984</LINK>), which are awaiting assessment for inclusion in our review and that we found not to support any of the suggested recommendations.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2017-03-09 17:24:51 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2017-02-14 11:52:30 +0000" MODIFIED_BY="[Empty name]">
<P>The literature lacks robust randomized clinical trials addressing the effect of benzodiazepines for restless legs syndrome (RLS). The effectiveness of benzodiazepines for RLS treatment is currently unknown.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2017-03-09 17:24:51 +0000" MODIFIED_BY="[Empty name]">
<P>It is highly recommended that new trials address the effectiveness of treating RLS with benzodiazepines. At present we do not know if this class of drugs, especially clonazepam that has been used for this purpose for decades, is beneficial for people with RLS. Trials should be designed carefully and should preferably be parallel-group design to avoid problems with a long carry-over effect of some benzodiazepines like clonazepam. Since RLS is a prevalent disease, studies should include appropriate sample sizes to ensure sufficient statistical power to detect clinically meaningful effects. Outcomes including improvement of RLS symptoms measured in valid scale, improvement of sleep quality, reduction of periodic leg movements in sleep (PLMS) index, and quality of life as a whole require evaluation. Since the impact of RLS may be different in other populations and cultures across the world, a comprehensive clinical trial would ideally be multinational. The absence of ongoing studies may reflect the lack of interest of clinical researchers in this class of drugs for RLS.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2017-03-09 17:24:46 +0000" MODIFIED_BY="[Empty name]">
<P>We are thankful for the immense help provided by the following people or institution: Mrs. Ema Roque; Mrs. Denise Mitchell; the editors of the Cochrane Movement Disorders Group; Escola Paulista de Medicina from Universidade Federal de São Paulo (UNIFESP); Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal Nível Superior (CAPES), Cochrane Editorial Unit (CEU) pre-publication, and all people involved in this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2017-02-14 11:55:23 +0000" MODIFIED_BY="[Empty name]">
<P>Karla Carlos: none known</P>
<P>Luciane Carvalho: none known</P>
<P>Lucila Prado: none known</P>
<P>Cristiane Fiquene Conti: none known</P>
<P>Marcio Moyses de Oliveira: none known</P>
<P>Gilmar Fernandes do Prado: none known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2017-02-14 11:55:07 +0000" MODIFIED_BY="[Empty name]">
<P>Karla Carlos: literature searching, study selection, data extraction, statistical analysis, drafting of written submissions, development of final review.</P>
<P>Luciane Carvalho: literature searching, study selection, data extraction, statistical analysis, drafting of written submissions, development of final review.</P>
<P>Lucila Prado: literature searching, study selection, data extraction, statistical analysis, drafting of written submissions, development of final review.</P>
<P>Cristiane Fiquene Conti: protocol development, literature searching.</P>
<P>Marcio Moyses de Oliveira: protocol development, literature searching.</P>
<P>Gilmar Fernandes do Prado: protocol development, literature searching, study selection, data extraction, statistical analysis, drafting of written submissions, development of final review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2017-03-09 17:24:40 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Cochrane methods</HEADING>
<P>Review updated with most recent Cochrane methodology: 'Risk of bias' assessments and GRADE system adopted for assessment of the quality of the evidence. This was necessary because Cochrane methodology has been improved since the protocol was written in 2008.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Dealing with missing data</HEADING>
<P>Added: our attempt to contact study authors as a means of obtaining such data</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup analysis</HEADING>
<P>Added: the variables gender, length of treatment, and ethnic group. RLS is more prevalent in women, and the risk factors and associated factors are also different. As it is a chronic disease, length of treatment should always be a variable of interest, both in terms of assessing adverse events and in terms of persistence of therapeutic effect, tolerance, and dependence, all of which are expected concerns with the benzodiazepine class. Some ethnic groups have a lower prevalence of RLS, and one may suppose their responses to interventions may differ as well.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Sensitivity analysis</HEADING>
<P>Added: the variable length of treatment, as the duration of intervention varies widely across studies:</P>
<OL>
<LI>age (children and adults)&#894;</LI>
<LI>severity (mild, moderate, severe)&#894;</LI>
<LI>gender;</LI>
<LI>length of treatment;</LI>
<LI>ethnic group;</LI>
<LI>medication.</LI>
</OL>
<P>These variables also play an important role in ensuring the robustness of the collected data and explaining the presence of heterogeneity.</P>
<P>In the Allocation item, substituted "lower quality" with "high risk of bias", the term used after implementation of the GRADE system.</P>
<P>
<B>Methods not implemented</B>
</P>
<P>We did not include any study, so we did not implemented the following items from the protocol: sensitivity analysis, heterogeneity analysis, subgroup analysis, all the applicable measures for continuous variables (mean difference (MD) and 95% Confidence Intervals (IC), or the standardised mean difference (SMD) and 95% CI, and dichotomous variables (risk ratio (RR) with 95% CI).</P>
</SUBSECTION>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-03-09 17:35:16 +0000" MODIFIED_BY="Ema Roque">
<STUDIES MODIFIED="2017-03-09 17:07:07 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-08-20 00:28:04 +0100" MODIFIED_BY="[Empty name]"/>
<EXCLUDED_STUDIES MODIFIED="2017-03-09 17:07:07 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Manconi-2012" MODIFIED="2017-03-09 17:07:07 +0000" MODIFIED_BY="[Empty name]" NAME="Manconi 2012" YEAR="2012">
<REFERENCE MODIFIED="2017-03-09 17:07:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manconi M, Ferri R, Zucconi M, Bassetti CL, Fulda S, Arico D, et al</AU>
<TI>Dissociation of periodic leg movements from arousals in restless legs syndrome</TI>
<SO>Annals of Neurology</SO>
<YR>2012</YR>
<VL>71</VL>
<PG>834-44</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5305656"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5305655"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2017-02-10 09:31:03 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Boghen-1986" MODIFIED="2017-02-10 09:30:30 +0000" MODIFIED_BY="[Empty name]" NAME="Boghen 1986" YEAR="1986">
<REFERENCE MODIFIED="2017-02-10 09:30:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boghen D, Lamothe L, Elie R, Godbout R, Montplaisir J</AU>
<TI>The treatment of the restless legs syndrome with clonazepam: a prospective controlled study</TI>
<SO>Canadian Journal of Neurological Sciences
</SO>
<YR>1986</YR>
<VL>13</VL>
<NO>3</NO>
<PG>245-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5305658"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5305657"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montagna-1984" MODIFIED="2017-02-10 09:31:03 +0000" MODIFIED_BY="[Empty name]" NAME="Montagna 1984" YEAR="1984">
<REFERENCE MODIFIED="2017-02-10 09:31:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montagna P, Sassoli de Bianchi L, Zucconi M, Cirignotta F, Lugaresi E</AU>
<TI>Clonazepam and vibration in restless legs syndrome</TI>
<SO>Acta Neurologica Scandinavica
</SO>
<YR>1984</YR>
<VL>69</VL>
<NO>6</NO>
<PG>428-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5305660"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5305659"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-03-09 17:21:36 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2017-03-09 17:21:36 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-AASM-2005" MODIFIED="2017-03-09 17:07:31 +0000" MODIFIED_BY="[Empty name]" NAME="AASM 2005" TYPE="BOOK">
<AU>American Academy of Sleep Medicine</AU>
<SO>International Classification of Sleep Disorders. Diagnostic and Coding Manual</SO>
<YR>2005</YR>
<EN>2nd</EN>
<PB>AASM</PB>
<CY>Westchester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allen-2001" MODIFIED="2017-03-09 17:08:13 +0000" MODIFIED_BY="[Empty name]" NAME="Allen 2001" TYPE="JOURNAL_ARTICLE">
<AU>Allen RP, Earley CJ</AU>
<TI>Validation of Johns Hopkins restless legs severity scale</TI>
<SO>Sleep Medicine</SO>
<YR>2001</YR>
<VL>2</VL>
<NO>3</NO>
<PG>239-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allen-2003" MODIFIED="2017-03-09 17:08:46 +0000" MODIFIED_BY="[Empty name]" NAME="Allen 2003" TYPE="JOURNAL_ARTICLE">
<AU>Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J, et al</AU>
<TI>Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health</TI>
<SO>Sleep Medicine</SO>
<YR>2003</YR>
<VL>4(2)</VL>
<PG>101-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allen-2004" MODIFIED="2017-03-09 17:09:01 +0000" MODIFIED_BY="[Empty name]" NAME="Allen 2004" TYPE="JOURNAL_ARTICLE">
<AU>Allen RP</AU>
<TI>Dopamine and iron in the pathophysiology of restless legs syndrome</TI>
<SO>Sleep Medicine</SO>
<YR>2004</YR>
<VL>(5)</VL>
<PG>385-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allen-2013" MODIFIED="2017-03-09 17:09:27 +0000" MODIFIED_BY="[Empty name]" NAME="Allen 2013" TYPE="JOURNAL_ARTICLE">
<AU>Allen RP, Auerbach S, Bahrain H, Auerbach M, Earley CJ</AU>
<TI>The prevalence and impact of restless legs syndrome on patients with iron deficiency anaemia</TI>
<SO>American Journal of Hematology</SO>
<YR>2013</YR>
<VL>88</VL>
<NO>4</NO>
<PG>261&#8211;4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ASDA-1990" MODIFIED="2017-03-09 17:10:00 +0000" MODIFIED_BY="[Empty name]" NAME="ASDA 1990" TYPE="BOOK">
<AU>American Sleep Disorders Association</AU>
<SO>Diagnostic Cassification Steering Committee. The International Classification of Sleep Disorders: Diagnostic and Coding Manual</SO>
<YR>1990</YR>
<PB>MN:ASDA</PB>
<CY>Rochester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aurora-2012" MODIFIED="2017-03-09 17:10:22 +0000" MODIFIED_BY="[Empty name]" NAME="Aurora 2012" TYPE="JOURNAL_ARTICLE">
<AU>Aurora RN, Kristo DA, Bista SR, Rowley JA, Zak RS, Casey KR, et al</AU>
<TI>Update to the AASM Clinical Practice Guideline: &#8220;The Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder in Adults&#8212;An Update for 2012: Practice Parameters with an Evidence-Based Systematic Review and Meta-Analyses&#8221;</TI>
<SO>Sleep</SO>
<YR>2012</YR>
<VL>35</VL>
<NO>8</NO>
<PG>1039-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bostwick-2012" MODIFIED="2017-03-09 17:10:45 +0000" MODIFIED_BY="[Empty name]" NAME="Bostwick 2012" TYPE="JOURNAL_ARTICLE">
<AU>Bostwick JR, Casher MI, Shinji Y</AU>
<TI>Benzodiazepines: a versatile clinical tool; evidence supports their use for alcohol withdrawal, insomnia, anxiety disorders, and other conditions</TI>
<SO>Current Psychiatry</SO>
<YR>2012</YR>
<VL>11</VL>
<PG>54-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brand-2013" MODIFIED="2017-03-09 17:11:04 +0000" MODIFIED_BY="[Empty name]" NAME="Brand 2013" TYPE="JOURNAL_ARTICLE">
<AU>Brand S, Beck J, Hatzinger M, Holsboer-Trachsler E</AU>
<TI>Patients suffering from restless leg syndrome have low internal locus of control and poor psychological functioning compared to healthy controls</TI>
<SO>Neuropsychobiology</SO>
<YR>2013</YR>
<VL>68</VL>
<PG>51-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carlos-2015" MODIFIED="2017-03-09 17:11:27 +0000" MODIFIED_BY="[Empty name]" NAME="Carlos 2015" TYPE="JOURNAL_ARTICLE">
<AU>Carlos K, Prado LBF, Carvalho LBC, Prado GF</AU>
<TI>Willis-Ekbom Disease or restless legs syndrome?</TI>
<SO>Sleep Medicine</SO>
<YR>2015</YR>
<VL>16</VL>
<PG>1156-9</PG>
<IDENTIFIERS MODIFIED="2016-03-15 20:27:34 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Corrigan-2012" MODIFIED="2017-03-09 17:11:44 +0000" MODIFIED_BY="[Empty name]" NAME="Corrigan 2012" TYPE="COCHRANE_REVIEW">
<AU>Corrigan R, Derry S, Wiffen PJ, Moore RA</AU>
<TI>Clonazepam for neuropathic pain and fibromyalgia in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2017-02-10 09:42:37 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-02-10 09:42:37 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD009486.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Daghero-1987" MODIFIED="2017-03-09 17:12:18 +0000" MODIFIED_BY="[Empty name]" NAME="Daghero 1987" TYPE="JOURNAL_ARTICLE">
<AU>Daghero AM, Bradley EL, Kissin I</AU>
<TI>Midazolam antagonizes the analgesic effect of morphine in rats</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>1987</YR>
<VL>66</VL>
<PG>944-7</PG>
<IDENTIFIERS MODIFIED="2016-03-22 23:30:14 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-DCSAD-1979" MODIFIED="2017-02-10 09:45:19 +0000" MODIFIED_BY="[Empty name]" NAME="DCSAD 1979" TYPE="JOURNAL_ARTICLE">
<AU>Association of Sleep Disorders Centers and the Association for the Psychophysiological Study of Sleep</AU>
<TI>Diagnostic classification of sleep and arousal disorders 1979 first edition
</TI>
<SO>Sleep</SO>
<YR>1979</YR>
<VL>2</VL>
<PG>1-154
</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2017-03-09 17:12:38 +0000" MODIFIED_BY="[Empty name]" NAME="Deeks 2011" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Earley-2013" MODIFIED="2017-02-10 09:45:42 +0000" MODIFIED_BY="[Empty name]" NAME="Earley 2013" TYPE="JOURNAL_ARTICLE">
<AU>Earley CJ, Kuwabara H, Wong DF, Gamaldo C, Salas RE, Bra&#353;ic JR, et al
</AU>
<TI>Increased synaptic dopamine in the putamen in restless legs syndrome
</TI>
<SO>Sleep</SO>
<YR>2013</YR>
<VL>36</VL>
<NO>1</NO>
<PG>51-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garcia_x002d_Borreguero-2013" MODIFIED="2017-03-09 17:13:03 +0000" MODIFIED_BY="[Empty name]" NAME="Garcia-Borreguero 2013" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Borreguero D, Kohnen R, Silber MH, Winkelman JW, Earley CJ, Högl B, et al</AU>
<TI>The long-term treatment of restless legs syndrome/Willis&#8211;Ekbom Disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group</TI>
<SO>Sleep Medicine</SO>
<YR>2013</YR>
<VL>14</VL>
<NO>7</NO>
<PG>675&#8211;84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gear-1997" MODIFIED="2017-03-09 17:13:40 +0000" MODIFIED_BY="[Empty name]" NAME="Gear 1997" TYPE="JOURNAL_ARTICLE">
<AU>Gear RW, Miaskowski C, Heller PH, Paul SM, Gordon NC, Levine JD</AU>
<TI>Benzoadizepine mediated antagonism of opioid analgesia</TI>
<SO>Pain</SO>
<YR>1997</YR>
<VL>71</VL>
<PG>25-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glass-2005" MODIFIED="2017-03-09 17:14:01 +0000" MODIFIED_BY="[Empty name]" NAME="Glass 2005" TYPE="JOURNAL_ARTICLE">
<AU>Glass J, Lanctôt KL, Herrmann N, Sproule BA, Busto UE</AU>
<TI>Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits</TI>
<SO>BMJ</SO>
<YR>2005</YR>
<VL>331</VL>
<PG>1169</PG>
<IDENTIFIERS MODIFIED="2017-02-10 09:47:50 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-02-10 09:47:50 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1136/bmj.38623.768588.47"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guilleminault-1990" MODIFIED="2017-03-09 17:13:24 +0000" MODIFIED_BY="[Empty name]" NAME="Guilleminault 1990" TYPE="JOURNAL_ARTICLE">
<AU>Guilleminault C</AU>
<TI>Benzodiazepines, breathing, and sleep</TI>
<SO>The American Journal of Medicine</SO>
<YR>1990</YR>
<VL>88</VL>
<NO>3</NO>
<PG>S25-8</PG>
<IDENTIFIERS MODIFIED="2013-10-17 22:54:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Hening-1999" MODIFIED="2017-02-10 09:51:31 +0000" MODIFIED_BY="[Empty name]" NAME="Hening 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hening W, Allen R, Earley C, Kushida C, Picchietti D, Silber M
</AU>
<TI>The treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine Review
</TI>
<SO>Sleep</SO>
<YR>1999</YR>
<VL>22</VL>
<PG>970-99
</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2017-03-09 17:14:21 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2017-03-09 17:14:56 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horguchi-1992" MODIFIED="2017-03-09 17:15:14 +0000" MODIFIED_BY="[Empty name]" NAME="Horguchi 1992" TYPE="JOURNAL_ARTICLE">
<AU>Horguchi J, Inami Y, Sasaki A, Nishimatsu O, Sukegawa T Nishimatsu O, et al</AU>
<TI>Periodic leg movements in sleep with restless legs syndrome: effect of clonazepam treatment</TI>
<SO>Japanese Journal of Psychiatry and Neurology</SO>
<YR>1992</YR>
<VL>19</VL>
<NO>3</NO>
<PG>180-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hornyak-2006" MODIFIED="2017-03-09 17:15:30 +0000" MODIFIED_BY="[Empty name]" NAME="Hornyak 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hornyak M, Feige B, Riemann D, Voderholzer U</AU>
<TI>Periodic leg movements in sleep and periodic limb movement disorder: prevalence, clinical significance and treatment</TI>
<SO>Sleep Medicine Reviews</SO>
<YR>2006</YR>
<VL>10</VL>
<PG>169&#8211;77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Howard-2014" MODIFIED="2017-03-09 17:15:45 +0000" MODIFIED_BY="[Empty name]" NAME="Howard 2014" TYPE="JOURNAL_ARTICLE">
<AU>Howard P, Twycross R, Shuster J, Mihalyo M</AU>
<TI>Benzodiazepine</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2014</YR>
<VL>47</VL>
<PG>955-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-H_x00fc_bner-2013" MODIFIED="2013-10-19 20:11:45 +0100" MODIFIED_BY="[Empty name]" NAME="Hübner 2013" TYPE="JOURNAL_ARTICLE">
<AU>Hübner A, Krafft A, Gadient S, Werth E, Zimmermann R, Bassetti CL</AU>
<TI>Characteristics and determinants of restless legs syndrome in pregnancy. A prospective study</TI>
<SO>Neurology</SO>
<YR>2013</YR>
<VL>80</VL>
<NO>8</NO>
<PG>738-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICSD-2014" MODIFIED="2017-02-10 09:56:08 +0000" MODIFIED_BY="[Empty name]" NAME="ICSD 2014" TYPE="BOOK">
<AU>American Academy of Sleep Medicine</AU>
<TI>

</TI>
<SO>The International Classification of Sleep Disorders - Third Edition (ICSD-3)</SO>
<YR>2014</YR>
<EN>3rd</EN>
<PB>American Academy of Sleep Medicine</PB>
<CY>Darien</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-IRLSSG-2003" MODIFIED="2017-03-09 17:16:09 +0000" MODIFIED_BY="[Empty name]" NAME="IRLSSG 2003" TYPE="JOURNAL_ARTICLE">
<AU>The International Restless Legs Syndrome Study Group</AU>
<TI>Validation of The International Restless Legs Syndrome Study Group rating scale for restless legs syndrome</TI>
<SO>Sleep Medicine</SO>
<YR>2003</YR>
<VL>4</VL>
<PG>121-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Joy-1997" MODIFIED="2017-03-09 17:16:24 +0000" MODIFIED_BY="[Empty name]" NAME="Joy 1997" TYPE="JOURNAL_ARTICLE">
<AU>Joy MS</AU>
<TI>Clonazepam: therapy for restless legs syndrome</TI>
<SO>ANNA</SO>
<YR>1997</YR>
<VL>24</VL>
<PG>686-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kurlan-2013" MODIFIED="2017-02-10 09:59:08 +0000" MODIFIED_BY="[Empty name]" NAME="Kurlan 2013" TYPE="JOURNAL_ARTICLE">
<AU>Kurlan R, Rabin M</AU>
<TI>Augmentation in restless legs syndrome: poor response to sudden withdrawal of dopaminergic therapy</TI>
<SO>Journal of Parkinsonism and Restless Legs Syndrome
</SO>
<YR>2013</YR>
<VL>3</VL>
<PG>49-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-2001" MODIFIED="2017-03-09 17:16:49 +0000" MODIFIED_BY="[Empty name]" NAME="Lee 2001" TYPE="JOURNAL_ARTICLE">
<AU>Lee KA, Zaffke ME, Baratte B</AU>
<TI>Restless legs syndrome and sleep disturbance during pregnancy: the role of folate and iron</TI>
<SO>Journal of Women's Health and Gender-Based Medicine</SO>
<YR>2001</YR>
<VL>10</VL>
<NO>4</NO>
<PG>335-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2017-03-09 17:17:32 +0000" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mirza-2013" MODIFIED="2017-03-09 17:17:55 +0000" MODIFIED_BY="[Empty name]" NAME="Mirza 2013" TYPE="JOURNAL_ARTICLE">
<AU>Mirza M, Shen Win-Kuang, Sofi A, Mori N, Tajik AJ, Jahangir A</AU>
<TI>Frequent periodic leg movement during sleep is associated with left ventricular hypertrophy and adverse cardiovascular outcomes</TI>
<SO>Journal of the American Society of Echocardiography</SO>
<YR>2013</YR>
<VL>26</VL>
<NO>7</NO>
<PG>783-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ohayon-2012" MODIFIED="2017-03-09 17:18:13 +0000" MODIFIED_BY="[Empty name]" NAME="Ohayon 2012" TYPE="JOURNAL_ARTICLE">
<AU>Ohayon MM, O'Hara R, Vitiello MV</AU>
<TI>Epidemiology of restless legs syndrome: a synthesis of the literature</TI>
<SO>Sleep Medicine Reviews</SO>
<YR>2012</YR>
<VL>16</VL>
<NO>4</NO>
<PG>283&#8211;95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Picchietti-2005" MODIFIED="2017-03-09 17:18:32 +0000" MODIFIED_BY="[Empty name]" NAME="Picchietti 2005" TYPE="JOURNAL_ARTICLE">
<AU>Picchietti D, Winkelman JW</AU>
<TI>Restless legs syndrome, periodic limb movements in sleep, and depression</TI>
<SO>Sleep</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>7</NO>
<PG>891-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Picchietti-2007" MODIFIED="2017-02-10 09:50:31 +0000" MODIFIED_BY="[Empty name]" NAME="Picchietti 2007" TYPE="JOURNAL_ARTICLE">
<AU>Picchietti D, Allen RP, Walters AS, Davidson JE, Myers A, Ferini-Strambi L</AU>
<TI>Restless legs syndrome: prevalence and impact in children and adolescents-the Peds REST study</TI>
<SO>Pediatrics</SO>
<YR>2007</YR>
<VL>120</VL>
<NO>2</NO>
<PG>253-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rizzo-2013" MODIFIED="2017-03-09 17:18:55 +0000" MODIFIED_BY="[Empty name]" NAME="Rizzo 2013" TYPE="JOURNAL_ARTICLE">
<AU>Rizzo G, Manners D, Testa C, Tonon C, Vetrugno R, Marconi S, et al</AU>
<TI>Low brain iron content in idiopathic restless legs syndrome patients detected by phase imaging</TI>
<SO>Movement Disorders</SO>
<YR>2013</YR>
<VL>13</VL>
<PG>1886-90</PG>
<IDENTIFIERS MODIFIED="2017-02-10 10:05:07 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-02-10 10:05:07 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/mds.25576"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rye-2012" MODIFIED="2017-03-09 17:19:13 +0000" MODIFIED_BY="[Empty name]" NAME="Rye 2012" TYPE="JOURNAL_ARTICLE">
<AU>Rye DB, Trotti LM</AU>
<TI>Restless legs syndrome and periodic leg movements of sleep</TI>
<SO>Neurologic Clinics</SO>
<YR>2012</YR>
<VL>30</VL>
<NO>4</NO>
<PG>1137&#8211;66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saletu-2001" MODIFIED="2017-03-09 17:19:34 +0000" MODIFIED_BY="[Empty name]" NAME="Saletu 2001" TYPE="JOURNAL_ARTICLE">
<AU>Saletu M, Anderer P, Saletu-Zyhlarz G, Prause W, Semler B, Zoghlamia A, et al</AU>
<TI>Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD): acute placebo-controlled sleep laboratory studies with clonazepam</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2011</YR>
<VL>11</VL>
<PG>153-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schenck-1996" MODIFIED="2017-03-09 17:20:02 +0000" MODIFIED_BY="[Empty name]" NAME="Schenck 1996" TYPE="JOURNAL_ARTICLE">
<AU>Schenck CH, Mahowald MW</AU>
<TI>Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults</TI>
<SO>The American Journal of Medicine</SO>
<YR>1996</YR>
<VL>100</VL>
<PG>333-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trenkwalder-2005" MODIFIED="2017-03-09 17:19:49 +0000" MODIFIED_BY="[Empty name]" NAME="Trenkwalder 2005" TYPE="JOURNAL_ARTICLE">
<AU>Trenkwalder C, Paulus W, Walters AS</AU>
<TI>The restless legs syndrome review</TI>
<SO>Lancet Neurology</SO>
<YR>2005</YR>
<VL>4</VL>
<NO>8</NO>
<PG>465-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walters-1995" MODIFIED="2017-03-09 17:20:26 +0000" MODIFIED_BY="[Empty name]" NAME="Walters 1995" TYPE="JOURNAL_ARTICLE">
<AU>Walters A, Aldrich M, Allen RP, Anconi-Israel S, Bucholz D, Chokroverty S, et al</AU>
<TI>Towards a better definition of the restless legs syndrome</TI>
<SO>Movement Disorders</SO>
<YR>1995</YR>
<VL>10</VL>
<PG>634-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetter-2004" MODIFIED="2017-03-09 17:20:55 +0000" MODIFIED_BY="[Empty name]" NAME="Wetter 2004" TYPE="JOURNAL_ARTICLE">
<AU>Wetter TC, Eisenensehr I ,Trenkwalder C</AU>
<TI>Functional neuroimaging studies in restless legs syndrome</TI>
<SO>Sleep Medicine</SO>
<YR>2004</YR>
<VL>5</VL>
<PG>401-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Winkelmann-2002" MODIFIED="2017-03-09 17:21:16 +0000" MODIFIED_BY="[Empty name]" NAME="Winkelmann 2002" TYPE="JOURNAL_ARTICLE">
<AU>Winkelmann J, Stautner A, Samtleben W, Trankwalder CW</AU>
<TI>Long-term course of restless legs syndrome in dialysis patients after kidney transplantation</TI>
<SO>Movement Disorders</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>5</NO>
<PG>1072-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yeh-2012" MODIFIED="2017-03-09 17:21:36 +0000" MODIFIED_BY="[Empty name]" NAME="Yeh 2012" TYPE="JOURNAL_ARTICLE">
<AU>Yeh P, Walters AS, Tsuang JW</AU>
<TI>Restless legs syndrome: a comprehensive overview on its epidemiology, risk factors, and treatment</TI>
<SO>Sleep and Breathing</SO>
<YR>2012</YR>
<VL>16</VL>
<PG>987-1007</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-03-09 17:24:08 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-08-20 00:28:04 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-02-14 11:56:56 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-08-24 15:15:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manconi-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-08-24 15:15:49 +0100" MODIFIED_BY="[Empty name]">
<P>Primary goal was PLMS treatment. Just one night of intervention. Different scales were used before and after intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>PLMS: periodic leg movements in sleep</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2017-03-09 17:24:08 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2017-03-09 17:24:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boghen-1986">
<CHAR_METHODS MODIFIED="2017-02-14 11:57:22 +0000" MODIFIED_BY="[Empty name]">
<P>Analysis: clonazepam vs placebo</P>
<P>Treatment duration: 4 weeks<BR/>Follow-up: not reported<BR/>Center: University of Montreal, Canada<BR/>Design: randomized clinical trial, double-blind, cross-over, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-02-14 11:57:34 +0000" MODIFIED_BY="[Empty name]">
<P>N = 6</P>
<P>Drop out: none<BR/>Diagnosis: clinically diagnosed</P>
<P>Exclusions: pregnant women, and people with systemic illness, such as diabetes and liver or renal diseases</P>
<P>Gender: 3 women, 3 men<BR/>Race: not reported</P>
<P>Age (years): 31&#8211;61 (mean 46)<BR/>Setting: University clinic</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-02-14 11:57:57 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: (n = 3) clonazepam (4 weeks) followed by placebo (4 weeks)</P>
<P>Group 2: (n = 3) placebo (4 weeks) followed by clonazepam (4 weeks)</P>
<P>Clonazepam was started at 0.5mg in the 1st week and progressively increased until the 4th week as follows: 1st week 1/2 h before bedtime; 2nd week 18:00 h, 3rd week at 12:00 h, and in the 4th at 8:00 h</P>
<P>Placebo = identical appearing</P>
<P>Washout = not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-02-14 11:58:03 +0000" MODIFIED_BY="[Empty name]">
<P>Self-rating system in which participants assigned a score daily to the degree of discomfort experienced in the previous 24 h (0-4)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-03-09 17:24:08 +0000" MODIFIED_BY="[Empty name]">
<P>Study authors seemed to be aware of the carry-over effect but they did not state if they allowed for it in the study.</P>
<P>We had no success in contacting the study authors for information about the cross-over results.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2017-02-14 12:00:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Montagna-1984">
<CHAR_METHODS MODIFIED="2017-02-14 11:59:37 +0000" MODIFIED_BY="[Empty name]">
<P>Analysis: clonazepam vs placebo vs vibration</P>
<P>Treatment duration: 1 week<BR/>Follow-up: not reported<BR/>Center: University of Bologna, Italy<BR/>Design: randomized clinical trial, double-blind, cross-over, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-02-14 11:59:43 +0000" MODIFIED_BY="[Empty name]">
<P>N = 6</P>
<P>Drop out: none<BR/>Diagnosis: clinical</P>
<P>Exclusions: not reported</P>
<P>Gender: 3 women, 3 men<BR/>Race: not reported</P>
<P>Age (years): mean 54.3 (range 44-64)<BR/>Setting: University Clinic</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-02-14 11:59:57 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: (n = 3) clonazepam</P>
<P>Group 2: (n = 3) placebo</P>
<P>Clonazepan 1 mg or placebo were taken 1/2 h before bedtime</P>
<P>Washout: 3 days between each treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-02-14 12:00:00 +0000" MODIFIED_BY="[Empty name]">
<P>4-point subjective scale to evaluate sleep quality, leg jerking, leg dysaesthesia</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-02-14 12:00:19 +0000" MODIFIED_BY="[Empty name]">
<P>Study authors also applied a 15-min vibration over one of the sural regions after the 1st phase protocol. That intervention and outcome was not blinded. Although the study authors compared drug and placebo intervention with vibration we did not consider their results in this review for the reason already stated, and because it was not stated in our protocol.</P>
<P>We had no success in contacting the study authors for information about the cross-over results.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-08-20 00:28:04 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-08-20 00:28:04 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-08-20 00:28:04 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-08-20 00:28:04 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-08-20 00:28:04 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-08-20 00:28:04 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-08-20 00:28:04 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-08-20 00:28:04 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-08-20 00:28:27 +0100" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-08-20 00:29:17 +0100" MODIFIED_BY="[Empty name]"/>
<FIGURES MODIFIED="2017-03-09 17:22:36 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-03-09 17:22:36 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAm0AAAI0CAYAAABPih6BAABBq0lEQVR42u3dD4RVef8H8IesJEkk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=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2017-03-09 17:23:46 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-11-06 15:56:22 +0000" MODIFIED_BY="Ema Roque" NO="1">
<TITLE MODIFIED="2008-11-06 15:54:55 +0000" MODIFIED_BY="Ema Roque">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-06 15:56:22 +0000" MODIFIED_BY="Ema Roque">
<P>"#1 RESTLESS LEGS SYNDROME<BR/>"#2 (restless next leg*)<BR/>"#3 (ekbom* next syndrome)<BR/>"#4 (periodic next leg next movements*)<BR/>"#5 (periodic next limb next movements*)<BR/>"#6 (PLM or PLMS or PLMD)<BR/>"#7 (#1 or #2 or #3 or #4 or #5 or #6)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-10-16 21:08:32 +0100" MODIFIED_BY="Ema Roque" NO="2">
<TITLE MODIFIED="2008-11-06 15:55:18 +0000" MODIFIED_BY="Ema Roque">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-16 21:08:32 +0100" MODIFIED_BY="Ema Roque">
<P>"MEDLINE search strategy (1966 to most recent):<BR/>"#1 restless legs syndrome [Text Word]<BR/>"#2 restless legs syndrome [All Fields]<BR/>"#3 ekbom syndrome [All Fields]<BR/>"#4 (periodic [All Fields] OR movement [All Fields]) AND (leg OR legs)<BR/>"#5 (periodic [All Fields] OR movement [All Fields]) AND (limb OR limbs)<BR/>"#6 (periodic [All Fields] OR movement [All Fields]) AND extremities [All Fields]<BR/>"#7 nocturnal myoclonus syndrome [All Fields]<BR/>"#8 periodic limb movement disorder<BR/>"#9 periodic limb movement disorders<BR/>"#10 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9<BR/>"#11 "clonazepam" [All Fields]<BR/>"#12 "temazepam" [All Fields]<BR/>"#13 "flurazepam" [All Fields]<BR/>"#14 "quazepam" [All Fields]<BR/>"#15 "estazolam" [All Fields]<BR/>"#16 "triazolam" [All Fields]<BR/>"#17 "alprazolam" [All Fields]<BR/>"#18 "diazepam" [All Fields]<BR/>"#19 "clobazam" [All Fields]<BR/>"#20 "lorazepam" [All Fields]<BR/>"#21 "oxazepam" [All Fields]<BR/>"#22 "zolpidem" [All Fields]<BR/>"#23 "zaleplon" [All Fields]<BR/>"#24 "zopiclone" [All Fields]<BR/>"#25 "eszopiclone" [All Fields]<BR/>"#26 #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25<BR/>"#27 #10 AND #26</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2017-03-09 17:23:46 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2017-03-09 17:23:46 +0000" MODIFIED_BY="[Empty name]">Embase search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-16 21:09:04 +0100" MODIFIED_BY="Ema Roque">
<P>"EMBASE search strategy (1980 to most recent):<BR/>"#1 Restless Legs Syndrome/<BR/>"#2 restless leg$.tw<BR/>"#3 Ekbom$ syndrome.tw<BR/>"#4 periodic leg movement$.tw<BR/>"#5 periodic limb movement$.tw<BR/>"#6 (PLM or PLMS or PLMD).tw<BR/>"#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6<BR/>"#8 "clonazepam.tw<BR/>"#9 "temazepam .tw<BR/>"#10 "flurazepam.tw<BR/>"#11 "quazepam .tw<BR/>"#12 "estazolam .tw<BR/>"#13 "triazolam.tw<BR/>"#14 "alprazolam .tw<BR/>"#15 "diazepam.tw<BR/>"#16 "clobazam .tw<BR/>"#17 "lorazepam.tw<BR/>"#18 "oxazepam.tw<BR/>"#19 "zolpidem.tw<BR/>"#20 "zaleplon.tw<BR/>"#21 "zopiclone.tw<BR/>"#22 "eszopiclone .tw<BR/>"#23 #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22<BR/>"#24 #7 AND #23</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2013-10-16 21:09:55 +0100" MODIFIED_BY="Ema Roque" NO="4">
<TITLE MODIFIED="2008-11-06 15:55:47 +0000" MODIFIED_BY="Ema Roque">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-16 21:09:55 +0100" MODIFIED_BY="Ema Roque">
<P>"LILACS search strategy (1982 to most recent):<BR/>"#1 síndrome das pernas inquietas [Palavras]".<BR/>"#2 (tw syndrome or tw sindrome) and (leg or legs or pierna$ or perna$ or limb$) [Palavras] and inquieta$ or restless<BR/>"#3 (movement$ and periodic) [Palavras]<BR/>"#4 #1 OR #2 OR #3<BR/>"#5 "clonazepam" [Palavras]<BR/>"#6 "temazepam" [Palavras]<BR/>"#7 "flurazepam" [Palavras]<BR/>"#8 "quazepam" [Palavras]<BR/>"#9 "estazolam" [Palavras]<BR/>"#10 "triazolam" [Palavras]<BR/>"#11 "alprazolam" [Palavras]<BR/>"#12 "diazepam" [Palavras]<BR/>"#13 "clobazam" [Palavras]<BR/>"#14 "lorazepam" [Palavras]<BR/>"#15 "oxazepam" [Palavras]<BR/>"#16 "zolpidem" [Palavras]<BR/>"#17 "zaleplon" [Palavras]<BR/>"#18 "zopiclone" [Palavras]<BR/>"#19 "eszopiclone" [Palavras]<BR/>"#20 #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19<BR/>"#21 #4 AND #20</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;2 studies are awaiting classification: no individual participant data for cross-over trials&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="286">
<FLOWCHARTBOX TEXT="&lt;p&gt;1400 records screened&lt;/p&gt;" WIDTH="130">
<FLOWCHARTBOX TEXT="&lt;p&gt;118 records duplicates removed&lt;/p&gt;" WIDTH="87">
<FLOWCHARTBOX TEXT="&lt;p&gt;1518 records identified through database searches&lt;/p&gt;" WIDTH="90"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1397 records excluded&lt;/p&gt;" WIDTH="146"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1 study was excluded: no direct treatment for RLS&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>